EFFECTIVENESS AND SAFETY OF PLATINUM BASED AGENTS NEOADJUVANT CHEMOTHERAPY ON PATHOLOGICAL COMPLETE RESPONSE IN TRIPLE NEGATIVE BREAST CANCER PATIENTS (A RETROSPECTIVE STUDY) | ||||
| Ain Shams Medical Journal | ||||
| Volume 75, Issue 2, June 2024, Page 337-347 PDF (583.39 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/asmj.2024.280363.1262 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ahmed Abdelaziz Elnaggar   1; Soheir Sayed Ismail2; Sherif Farouk Elzawawy3; Reham Mohamed Faheim2; Khaled Naguib AbdelHakim2
| ||||
| 1Department of Clinical Oncology, Faculty of medicine Tanta University, Tanta, Egypt. | ||||
| 2Department of Clinical Oncology and Nuclear Medicine, Faculty of medicine, Ain Shams University, Cairo, Egypt. | ||||
| 3Department of Clinical Oncology and Nuclear Medicine, Faculty of medicine Alexandria University, Alexandria, Egypt. | ||||
| Abstract | ||||
| Background: Triple-negative breast cancer(TNBC) is highly aggressive with mortality rates higher than hormone-positive because of the shortage of applied therapy. The main approach for TNBC patients was the neoadjuvant chemotherapy (NACT) to achieve pathological complete response (pCR). The ultimate goal of pCR is to improve local outcomes, event-free and overall survival (OS). adding platinum-based agents to NACT showing promising activity in achieving pCR in TNBC. Study objective: To stand out the role of adding platinum-based agents to NACT in enhancing pCR rates in TNBC patients. Also, to evaluate the safety of platinum-based agents concerning complications. Materials and Method: Retrospective study comprised medical records from 80 TNBC patients divided into 2 groups (40/group) treated with NACT either platinum free or platinum-based protocol from 2017 to 2022 at oncology department of both Ain shams and Alexandria university hospitals. Results: Median age was 48.5. 50% were postmenopausal. 55% of the patients were T3, T4. 45% had positive LNS. pCR rates were favourable in platinum-based group, 17 patients (42.5%) achieved pCR, 23 patients (57.5%) had residuals while in platinum-free group, 9 patients (22.5%) achieved pCR, 31 patients (77.5%) had residuals with significant difference assessment by Pearson’s Chi-square Test=3.647, P=0.047. Platinum based group had higher incidence of grade 3,4 complications than platinum free group shown with odds ratio 2.17 in thrombocytopenia, 3 in nausea and vomiting, lastly 5.57 in nephropathy. Conclusion: In TNBC patients, adding platinums to NACT is associated with higher pCR rates with mild complications so it may be considered an optional treatment. | ||||
| Keywords | ||||
| Breast cancer; Triple negative; pCR; Neoadjuvant; Platinum based agents | ||||
|
Statistics Article View: 132 PDF Download: 109 |
||||
